JAK2 and acute lymphoblastic leukemia: Although the underlying mechanisms were not shown, a recent study demonstrated that the USP9X inhibitor BRD0476 downregulated JAK2 signaling also in a subtype of acute lymphoblastic leukemia (ALL) that shows hyperactivation of JAK2 with or without the activating R683G mutation [36].